Sidney Pestka

6482613, Nov 19, 2002

Jan 19, 1988

07/145002

David V. Goeddel - Burlingame CA
Sidney Pestka - North Caldwell NJ

Hoffmann-La Roche Inc. - Nutley NJ
Genentech, Inc. - South San Francisco CA

C12P 2102

435 6951, 435 691, 4352523, 43525233, 536 2352

Disclosed herein are methods and means of microbially producing, via recombinant DNA technology, mature human leukocyte interferons, useful in the treatment of viral and neoplastic diseases.

6514753, Feb 4, 2003

Feb 8, 1999

09/246830

Sidney Pestka - North Caldwell NJ

PBL Biomedical Laboratories, Inc. - Piscataway NJ

C12N 1563

4353201, 536 231, 536 234, 435 691, 435 697, 435 711, 435 712, 4352523

Modified proteins, modified interferons s and s, phosphorylated modified proteins and DNA sequences encoding the above, applications and uses thereof. Modified phosphorylated Hu-IFN--like proteins are provided which carry an identifiable label such as a radio-label. Corresponding phosphorylatable Hu-IFN--like proteins which contain a putative phosphorylation site. DNA sequences which encode a Hu-IFN--like protein and contain a sequence encoding a putative phosphorylatable site. Appropriate expression vectors are used to transform compatible host cells of various microorganisms, such as. Numerous uses for the phosphorylated proteins are disclosed.

6610830, Aug 26, 2003

Apr 21, 1981

06/256204

David V. Goeddel - Burlingame CA
Sidney Pestka - North Caldwell NJ

Hoffman-La Roche Inc. - Nutley NJ
Genentech, Inc. - South San Francisco CA

C07K 1456

530351, 435 6951, 536 2352

Disclosed herein are methods and means of microbially producing, via recombinant DNA technology, mature human leukocyte interferons, useful in the treatment of viral and neoplastic diseases.

6747131, Jun 8, 2004

Nov 28, 2000

09/723942

Sidney Pestka - North Caldwell NJ

Pestka Biomedical Laboratories, Inc.

C07K 1456

530352, 435 6951, 435 697, 435325, 435471, 4352523, 4353201, 435 712, 424 141, 536 234, 536 2352, 530351, 530399

Modified proteins, modified interferons s and s, phosphorylated modified proteins and DNA sequences encoding the above, applications and uses thereof. Modified phosphorylated Hu-IFN--like proteins are provided which carry an identifiable label such as a radio-label. Corresponding phosphorylatable Hu-IFN--like proteins which contain a putative phosphorylation site. DNA sequences which encode a Hu-IFN--like protein and contain a sequence encoding a putative phosphorylatable site. Appropriate expression vectors are used to transform compatible host cells of various microorganisms, such as. Numerous uses for the phosphorylated proteins are disclosed.

6800747, Oct 5, 2004

Nov 28, 2000

09/723775

Sidney Pestka - North Caldwell NJ

Pestka Biomedical Laboratories, Inc.

C12N 510

536 234, 435 697, 4352523, 43525411, 4353201, 435471, 435325, 530351, 530399

Modified proteins, modified interferons s and s, phosphorylated modified proteins and DNA sequences encoding the above, applications and uses thereof. Modified phosphorylated Hu-IFN--like proteins are provided which carry an identifiable label such as a radio-label. Corresponding phosphorylatable, Hu-IFN--like proteins which contain a putative phosphorylation site. DNA sequences which encode a Hu-IFN--like protein and contain a sequence encoding a putative phosphorylatable site. Appropriate expression vectors are used to transform compatible host cells of various microorganisms, such as Numerous uses for the phosphorylated proteins are disclosed.

7129331, Oct 31, 2006

May 31, 2001

09/872349

Sidney Pestka - North Caldwell NJ, US

Pestka Biomedical Laboratories, Inc. - Piscataway NJ

A61K 38/00

5303873, 5303871

Methods to generate modified polypeptides, modified antibodies, stably phosphorylated modified polypeptides, stably phosphorylated modified antibodies, polynucleotide sequences encoding the polypeptides, and uses thereof are provided. A computer-aided molecular modeling method is also provided to generate modified phosphorylatable polypeptides, particularly monoclonal antibodies (MAbs) for use in the diagnosis and treatment of cancers and other diseases. The corresponding MAbs contain heterologous recognition sites for polypeptide kinases and can be labeled by an identifiable label, such as radio-isotope P. The phosphate group(s) attached to the phosphorylated polypeptide is unusually stable due to engineered intramolecular interactions between the phosphate group and its neighbouring groups. Polynucleotide sequences which encode a monoclonal antibody containing sequences encoding a putative phosphorylation site, and methods for analyzing the biochemical properties of a polypeptide by using molecular modeling tools, are also disclosed.

7666995, Feb 23, 2010

Nov 5, 2001

10/415969

Sidney Pestka - North Caldwell NJ, US

Pestka Biomedical Laboratories - Piscataway NJ

C07K 14/52
C12N 15/21
A61K 38/21

530351, 435 6951, 424 854

The present disclosure provides isolated Interferonα nucleic acids and polypeptides. The disclosure also provides antibodies which specifically recognize the subject Interferonα polypeptides, expression vectors containing the subject nucleic acids, and host cells expressing the subject polypeptides. In addition, methods of treatment using Interferonα are provided.

7956161, Jun 7, 2011

Apr 11, 2008

12/082815

Michael A. Skawinski - Fanwood NJ, US
Doranelly Koltchev - West Windsor NJ, US
Ronald Jubin - Watchung NJ, US
William A. Clark - Matawan NJ, US
Thomas B. Lavoie - Califon NJ, US
Sidney Pestka - North Caldwell NJ, US

Pestka Biomedical Laboratories, Inc. - Piscataway NJ

C07K 14/52
C07K 14/00
G01N 33/53
A61K 38/21
A61K 38/00

530351, 530350, 436501, 424 854, 424 857, 514 12

Disclosed are interferons of Rhesus and Cynomolgus origin and methods of production and use thereof.